Verve Therapeutics Overview

  • Founded
  • 2018
Founded
  • Status
  • Public
  • Employees
  • 73
Employees
  • Stock Symbol
  • VERV
Stock Symbol
  • Share Price
  • $26.99
  • (As of Monday Closing)

Verve Therapeutics General Information

Description

Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.

Contact Information

Website
www.vervetx.com
Formerly Known As
Endcadia
Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 500 Technology Square
  • Suite 901
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Verve Therapeutics Timeline

2019202020212022
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Verve Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$26.99 $27.65 $24.75 - $78.00 $1.33B 48.2M 640K -$6.34

Verve Therapeutics Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 1,837,991
Revenue 0 0 0
EBITDA (111,268) (44,538) (19,469)
Net Income (112,508) (45,704) (19,297)
Total Assets 410,877 78,413 21,647
Total Debt 2,476 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Verve Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Verve Therapeutics‘s full profile, request access.

Request a free trial

Verve Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Verve Therapeutics‘s full profile, request access.

Request a free trial

Verve Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatm
Drug Discovery
Cambridge, MA
73 As of 2021
00000
0000 0000-00-00
00000000 00000

00000000

gna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Bannockburn, IL
000 As of 0000
00000
0.00 0000-00-00
000000&0 00000

0000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitatio
0000000000000
New York, NY
00 As of 0000
00000
0000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Verve Therapeutics Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Gene Therapies Formerly VC-backed Bannockburn, IL 000 00000 000000&0 00000
0000000 0000000000 Formerly VC-backed New York, NY 00 00000 000000&0 00000
0000000000 0000000 Formerly VC-backed Novato, CA 0000 00000 000000000 00000
0000 000000000000 Venture Capital-Backed Larnaca, Cyprus 00 00.000 0000000000 0 00.000
000000 00000000000 Formerly VC-backed Watertown, MA 000 00000 00000000 00000
You’re viewing 5 of 50 competitors. Get the full list »

Verve Therapeutics Patents

  • 1

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Verve Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210299261-A1 Compositions and methods for targeted rna delivery Pending 04-Mar-2020 00000000

Verve Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Andrew Ashe JD President & Chief Operating Officer
Allison Dorval Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Andrew Bellinger Ph.D Chief Scientific Officer
J. Keith Joung Ph.D Scientific Co-Founder and Consultant
Yasser El-Gamal JD Executive & Vice President
You’re viewing 5 of 15 executive team members. Get the full list »

Verve Therapeutics Board Members (11)

Name Representing Role Since
Anthony Philippakis Ph.D Verve Therapeutics Co-Founder & Board Member 000 0000
Barry Ticho MD Self Co-Founder & Board Member 000 0000
Boris Nikolic MD Biomatics Capital Board Observer 000 0000
Burt Adelman MD Verve Therapeutics Chairman & Board Member 000 0000
Eli Casdin Casdin Capital Board Observer 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Verve Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verve Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Verve Therapeutics‘s full profile, request access.

Request a free trial